The American Society for Colposcopy and Cervical Pathology (ASCCP) has issued new guidelines reflecting the importance of extended genotyping in HPV testing to support an enhanced standard of patient care.

BD Onclarity™ HPV Assay is the first FDA-approved HPV assay that individually identifies 6 genotypes to be cited in guidelines for the clinical management of a positive HPV test result, also offering the option of self-collection in a healthcare setting.

Join us for a 60-minute webinar, exploring the role self-collection in a healthcare setting and extended genotyping, focusing on the new ASCCP HPV Testing Guidelines, reporting and relevance of extended genotyping results.

You’ll learn about:

• Extended genotyping, its importance in providing enhanced patient care and result reporting.
• How to correctly code to capture the new reimbursement rate associated with HPV tests that incorporate extended genotyping.
• Self-collection in a healthcare setting and associated workflows.